Latest Competition News

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.

Harris Technology Group reported a 17% revenue decline for FY25 but improved its net loss by nearly 32%, driven by a pivot towards higher-margin refurbished IT products and tighter inventory management.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Simble Solutions Limited reported a 21.3% revenue decline and a $646,578 net loss for H1 2025, while raising $807,375 to fund strategic growth in renewable energy and AI integration.

Wiseway Group has reported a striking 66% increase in revenue for FY25, driven by robust expansion in its Imports and Overseas divisions alongside a nearly sevenfold rise in net profit before tax.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.

Wiseway Group has delivered its strongest financial performance since listing, powered by a booming US division and a sharp focus on eCommerce imports across key markets.

Wiseway Group Limited has reported a remarkable 66% increase in revenue for FY2025, driven by strong operational performance and strategic expansion into the US market. The company also declared a final dividend, signalling confidence in its growth trajectory.

Pure Hydrogen Corporation has had its trading suspension lifted immediately following a capital raising announcement, signaling renewed market activity for the energy company.

Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

OM Holdings reported a slight revenue increase in the first half of 2025 but faced a loss due to falling ferrosilicon prices, while maintaining strong cash flow and preparing key asset sales.